Ethan Settembre

This inventor holds 10 USPTO granted patents and 4 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Glaxosmithkline Biologicals Sa, Novartis Ag, Seqirus UK Limited. Active years: 2017-2024.

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 80.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 11)

Average Co-Inventor Count = 2.9

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Cambridge, MA (US) (2019 - 2022)
Lexington, MA (US) (2017 - 2024)

Company Filing History:

3 out of 545

Glaxosmithkline Biologicals Sa

Years Active: 2017-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11896636 - Immunogenic combination compositions and uses thereof (2024-02-13),

2. 11249088 - Influenza potency assays (2022-02-15),

3. 11013795 - Antigenically matched influenza vaccines (2021-05-25),

4. 10416171 - Influenza potency assays (2019-09-17),

5. 10364273 - Cytomegalovirus antigens (2019-07-30),

6. 10287324 - Norovirus derived immunogenic compositions and methods (2019-05-14),

7. 10192025 - Rotavirus particles with chimeric surface proteins (2019-01-29),

8. 10065994 - Norovirus derived immunogenic compositions and methods (2018-09-04),

9. 10030052 - Parvovirus Vp1 unique region polypeptides and compositions thereof (2018-07-24),

10. 9744228 - Method for generating a parvovirus B19 virus-like particle (2017-08-29),

Title: Ethan Settembre: Innovator in Immunogenic Compositions

Introduction: Ethan Settembre, hailing from Cambridge, MA, has established himself as a prominent figure in the field of immunology with a remarkable portfolio of ten patents. His work focuses on innovative approaches to vaccine development, combining scientific rigor with real-world applications.

Latest Patents: Among his latest contributions, two notable patents stand out. The first is centered on immunogenic combination compositions, involving a unique design that incorporates an RNA component alongside a polypeptide component. This groundbreaking invention effectively delivers antigens from two pathogens, enhancing the immune response against both threats. The second patent addresses influenza potency assays, presenting stability-indicating methods for evaluating the potency of influenza vaccines, ensuring safer and more effective immunization.

Career Highlights: Ethan has built his career with significant stints at renowned companies, including Novartis AG and Seqirus UK Limited. His experience in these leading pharmaceutical establishments has equipped him with the expertise needed to drive innovations in vaccine technology.

Collaborations: Throughout his journey, Ethan has collaborated with several distinguished professionals in the field, including Philip R Dormitzer and Angelica Medina-Selby. These collaborations have enriched his research, fostering an environment of shared knowledge and innovation.

Conclusion: With ten patents and a dedication to advancing immunological research, Ethan Settembre is a key innovator in his field. His contributions continue to push the boundaries of vaccine development, paving the way for more effective public health solutions.